3-氨基-1H-吲唑-6-醇 | 88805-72-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 中文名称: 3-氨基-1H-吲唑-6-醇
• 中文别名: 3-氨基-6-羟基-1H-吲唑
• 英文名称: 3-Amino-1H-indazol-6-ol
• CAS: 88805-72-5
• 化学式: C₇H₇N₃O
• mdl: MFCD08458990
• 分子量: 149.15
• InChiKey: GPNYASFPMYCHKY-UHFFFAOYSA-N

物化性质

• 沸点：
  476.4±25.0 °C(Predicted)
• 密度：
  1.556±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  74.9
• 氢给体数：
  3
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090

文献信息

• Indazole derivatives
  申请人：Asahi Kasei Kogyo Kabushiki Kaisha

  公开号：EP0090972A2

  公开（公告）日：1983-10-12

  A compound of the formula (I): wherein W, and W2 each independently is a hydrogen atom or a group wherein Y is a n-C1-6 alkvlene group or a n-C1-6 alkylene group having a C1-6 alkyl group substituent; and R, and R2 each independently is a hydrogen atom or a C1-5 alkyl group, and group in group may form a saturated heterocyclic ring selected from the group consisting of morphohno. pyrrolidino, piperidino, homopiperidino and piperazino groups. and the saturated heterocyclic ring except the morpholino group may have at least one C1-4 alkyl group, hydroxyl group or halogen atom as a substituent; Z, is a hydrogen atom, a chlorine atom, a bromine atom, an iodine atom, a hydroxyl group, an amino group, a C1-3 alkyl group or a methoxy group; Z2 is a hydrogen atom or an amino group; when W, and W2 are both hydrogen atoms, Z, is a hydroxyl group or an iodine atom and Z2 is hydrogen atom, or Z, and 22 are both amino groups; When Z, and 22 are both hydrogen atoms, the group in either W, or W2 is a morpholino group; when Z, is a chlorine atom, a hydroxyl group, an iodine atom, a methyl group or a methoxy group, Z2 is a hydrogen atom; when Z, is an amino group, Z2 is a hydrogen atom or an amino group; when Z, is a methyl group, a methoxy group or an amino group, Z, is in the 5-position; when Z, is an iodine atom, Z, is in the 5- or 7-position; and when Z, and Z2 are both amino groups. Z, and Z2 are in the 5- and 7-positions; and the physiologically acceptable acid addition salt thereof.

  式 (I) 的化合物： 其中 W和W2各自独立地为氢原子或基团，其中 其中 Y 是 n-C1-6 烯基或具有 C1-6 烷基取代基的 n-C1-6 烯基；以及 R 和 R2 各自独立地是氢原子或 C1-5 烷基，且 中的基团 除吗啉基外，饱和杂环可具有至少一个 C1-4 烷基、羟基或卤原子作为取代基； Z 是氢原子、氯原子、溴原子、碘原子、羟基、氨基、C1-3 烷基或甲氧基； Z2 是氢原子或氨基； 当 W 和 W2 都是氢原子时，Z 是羟基或碘原子，Z2 是氢原子，或 Z 和 22 都是氨基； 当 Z 和 22 均为氢原子时，则 当 Z 和 22 均为氢原子时，W 或 W2 中的基团为吗啉基； 当 Z 为氯原子、羟基、碘原子、甲基或甲氧基时，Z2 为氢原子； 当 Z 为氨基时，Z2 为氢原子或氨基； 当 Z 是甲基、甲氧基或氨基时，Z 在 5 位；当 Z 是碘原子时，Z 在 5 或 7 位；当 Z 和 Z2 都是氨基时。Z和Z2分别位于5和7位；及其生理学上可接受的酸加成盐。
• Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
  申请人：Pfizer Italia S.r.l.

  公开号：EP1820503A2

  公开（公告）日：2007-08-22

  Compounds which are 3-aminoindazole derivatives or pharmaceutically acceptable salts thereof, together with pharmaceutical compositions comprising them are disclosed; these compounds or compositions are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune diseases and neurodegenerative disorders.

  本研究公开了 3-氨基吲唑衍生物或其药学上可接受的盐类化合物，以及包含它们的药物组合物；这些化合物或组合物可用于治疗由蛋白激酶活性改变引起和/或与之相关的疾病，如癌症、细胞增殖性疾病、阿尔茨海默病、病毒感染、自身免疫性疾病和神经退行性疾病。
• AMINOINDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
  申请人：Pfizer Italia S.r.l.

  公开号：EP1432416B1

  公开（公告）日：2011-01-19
• US4533731A
  申请人：——

  公开号：US4533731A

  公开（公告）日：1985-08-06
• US7511136B2
  申请人：——

  公开号：US7511136B2

  公开（公告）日：2009-03-31